FDA fast-tracks two Merck (MRK) drugs with blockbuster potential
I'm PortAI, I can summarize articles.
The FDA has fast-tracked reviews of two experimental drugs from Merck & Co., Inc. (NYSE:MRK), which have multibillion-dollar potential. This development comes as Merck is also recognized among the 14 Best Pharma Dividend Stocks to Buy in 2026.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments